New combo therapy shows promise for tough lung cancer

NCT ID NCT04745689

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy. The goal is to see if this approach improves how long people live without their cancer getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Grand Rapids, Michigan, 49503, United States

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Poznan, 60-693, Poland

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Jinju, 52727, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Seville, 41071, Spain

  • Research Site

    Valencia, 46015, Spain